Ondondo B., Brennan C., Nicocia A., Crome S.J., Hanke T. Absence of systemic toxicity changes following intramuscular administration of novel pSG2∙HIVconsv DNA, ChAdV63∙HIVconsv and MVA∙HIVconsv vaccines to BALB/c mice. Vaccine. 2013; 31(47):5594–601. DOI: 10.1016/j.vaccine.2013.06.068..
DOI: 10.1016/j.vaccine.2013.06.068
Ondondo B., Abdul-Jawad S., Bridgeman A., Hanke T. Characterization of T-cell responses to conserved regions of the HIV proteome in BALB/c mice. Clin. Vaccine Immunol. 2014; 21(11):1565–72. DOI: 10.1128/CVI.00587-14..
DOI: 10.1128/CVI.00587-14
Hopkins R., Bridgeman A., Joseph J., Gilbrt S.C., McShane H., Hanke T. Dual neonate vaccine platform against HIV-1 and M. tuberculosis. PLoS ONE. 2011; 6(5):e20067. DOI: 10.1371/journal.pone.0020067..
DOI: 10.1371/journal.pone.0020067
Earl P.L., Cotter C., Moss B., VanCott T., Currier J., Eller L.A., McCutchan F., Birx D.L., Michael N.L., Marovich M.A., Robb M., Cox J.H. Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine. 2009; 27(42):5885–95. DOI: 10.1016/j.vaccine.2009.07.039..
DOI: 10.1016/j.vaccine.2009.07.039
Guerra S., González J.M., Climent N., Reuburn H., LópezFernández L.A., Nájera J.L., Gómez C.E., García F., Gatell J.M., Gallart T., Esteban M. Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J. Virol. 2010; 84(16):8141– 52. DOI: 10.1128/jvi.00749-10..
DOI: 10.1128/jvi.00749-10
Saubi N., Mbewe-Mvula A., Gea-Mallorqui E., Rosario M., Gatell J.M., Hanke T., Joseph J. Pre-clinical development of BCG∙HIVACAT, an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG. PLoS ONE. 2012; 7(8):e42559. DOI: 10.1371/journal.pone.0042559..
DOI: 10.1371/journal.pone.0042559
Saubi N., Gea-Mallorqui E., Ferrer P., Hurtado C., SanchezUbeda S., Eto Y., Gatell J.M., Hanke T., Joseph J. Engineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG. Mol. Ther. Methods Clin. Dev. 2014; 1:14017. DOI: 10.1038/mtm.2014.17..
DOI: 10.1038/mtm.2014.17
Chapman R., Shephard E., Stutz H., Douglass N., Sambandamurthy V., Gfrcia I., Ryffel B., Jacobs W., Williamson A-L. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T-cells. PLoS ONE. 2012; 7(3):e32769. DOI: 10.1371/journal.pone.0032769..
DOI: 10.1371/journal.pone.0032769
Rosario M., Hopkins R., Fulkerson J., Borthwik N., Quigley M.F., Joseph J., Douekh D.C., Greenaway H.Y., Venturi V., Gostick E., Price D.A., Both G.W., Sadoff J.C., Hanke T. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques. J. Virol. 2010; 84(12):5898–908. DOI: 10.1128/JVI.02607-09..
DOI: 10.1128/JVI.02607-09
Ami Y., Izumi Y., Matsuo K., SomeyaK., Kanekiyo., Horibata S., Yoshino N., Sakai K., Shinohara K., Matsumoto S., Yamada T., Yamazaki S., Yamamoto N., Honda M. Primingboosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerinand a nonreplicationvaccinia virus recombinant leads to long-lasting and effective immunity. J. Virol. 2005; 79(20):12871–9. DOI: 10.1128/JVI.79.20.12871-12879.2005..
DOI: 10.1128/JVI.79.20.12871-12879.2005
Rosario M., Fulkerson J., Soneji S., Parker J., Im E-J., Borthwick N., Bridgeman A., Bourne C., Joseph J., Sadoff C.S., Hanke T. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques. J. Virol. 2010; 84(15):7815–21. DOI: 10.1128/JVI.00726-10..
DOI: 10.1128/JVI.00726-10
Borthwick N.J., Rosario M., Schiffner T.E., Ahmed T., Liljestrom P., Stewart-Jones G.T., Drijhout J.W., Melief C.J.M., Hanke T. Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques. Immun. Inflame. Dis. 2015; 3(2):82–93. DOI: 10.1002/iid3.52..
DOI: 10.1002/iid3.52
Garber D.A., O’Mara L.A., Gangadhara S., McQuoid M., Zhang X., Zheng R., Gill K., Verma M., Yu T., Johnson B., Derdeyn C.A., Ibegbu C., Altman J.D., Hunter E., Feinberg M.B. Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J. Virol. 2012; 86(23):12605–15. DOI: 10.1128/jvi.00246-12..
DOI: 10.1128/jvi.00246-12
García-Arriaza J., Arnáez P., Gómez C., Sorzano C.Ó.S., Esteban M. Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways. PLoS ONE. 2013; 8(6):e66894. DOI: 10.1371/journal.pone.0066894..
DOI: 10.1371/journal.pone.0066894
VijayanA., Garcia-Arriaza J., Raman S.C., Conesa J.J., Chichón F.G., Santiago C., Sorzano C.O.S., Carrascosa J.L., Esteban M. A chimeric HIV-1 gp120 fused with vaccinia virus 14K (A27) protein as an HIV immunogen. PLoS ONE. 2015; 10(7):e0133595. DOI: 10.1371/journal.pone.0133595..
DOI: 10.1371/journal.pone.0133595
Shen X., Basu R., Sawant S., Beaumont D., Kwa S-F., LaBranche C., Seaton K.E., Yates N.L., Montefiori D. Ferrari., Wyatt L.S., Moss B. Alam S.M., Haynes B.F., Tomaras G.D., Robinson H.L. HIV-1 gp120 and modified vaccinia virus Ankara MVA gp140 boost immunogens increase immunogenicity of a DNA/MVA HIV vaccine. J. Virol. 2017; 91(24):e01077-17. DOI: 10.1128/jvi.01077-17..
DOI: 10.1128/jvi.01077-17
Jones A.T., Chamcha V., Kesavardhana S., Shen X., Beaumont D., Das R., Wyatt L.S., LaBranche C.C., Stanfield-Oakley S., FerraryG., Montefiori D.C., Moss B., Tomaras G.D., Varadarajan R., Amara R.R. A trimeric HIV-1 Envelope gp120 immunogen induces potent and broad anti-v1v2 loop antibodies against HIV-1 in rabbits and rhesus macaques. J. Virol. 2018; 92(5):e91796-17. DOI: 10.1128/JVI.01796-17..
DOI: 10.1128/JVI.01796-17
Capucci S. Wee E.G., Schiffner T., LaBranche C.C., Borthwick N., Cupo A., Dodd J., Dean H., Sattentau Q., Montefiori D., Klasse P.J., Sanders R.W., Moore J.P., Hanke T. HIV-1 neutralizing antibody induced by simian adenovirusand poxvirus MCAvectored BG505 native-like envelope trimers. PLoS ONE. 2017; 12(8):e0181886. DOI: 10.1371/journal.pone.0181886..
DOI: 10.1371/journal.pone.0181886
Knudsen M.L., Ljungberg K., Tatoud R., Weber J., Esteban M., Liljeström P. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen. PLoS ONE. 2015; 10(2):e0117042. DOI: 10.1371/journal.pone.0117042..
DOI: 10.1371/journal.pone.0117042
Roshorm Y., Cottingham M.G., Potash M-J., Volsky D.J., Hanke T. T cell induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load. Eur. J. Immunol. 2012; 42(12):3243–55. DOI: 10.1002/eji.201242624..
DOI: 10.1002/eji.201242624
Ourmanov I., Kuwata T., Goeken R., Goldstein S., Iyengar R., Buckler-White A., Lafont B., Hirsch V.M. Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody. J. Virol. 2009; 83(11):5388–400. DOI: 10.1128/JVI.02598-08..
DOI: 10.1128/JVI.02598-08
Lai L.L., Kwa S-F., Kozlowski P.A., Montefiori D.C., Nolen T., Hudgens M.G., Johnson W.E., Ferrari G., Hirsch V.M., Felber B.K., Pavlakis G.N., Earl P., Moss B., Amara R.A., Robinson H.L. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine. 2012; 30(9):1737–45. DOI: 10.1016/j.vaccine.2011.12.026..
DOI: 10.1016/j.vaccine.2011.12.026
Kannanganat S., Nigam P., Velu V., Earl P.L, Lai L., Chennareddi L., Lawson B., Wilson R.L., Montefiori D.C., Kozlowski P.A., Moss B., Robinson H.L., Amara R.R. Preexisting vaccinia virus immunity decrease SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine. J. Immunol. 2010; 185(12):7262–73. DOI: 10.4049/jimmunol.1000751..
DOI: 10.4049/jimmunol.1000751
Engram J.C., Dunham R., Makedonas G., Vanderfor T.H., Sumpter B., Klatt N.R., Ratcliffe S.J., Garg S., Piardini M., McQuoid M., Altman J.D., Staprans S.I., Bets M.R., Garber D.A., Feinberg M.V., Silvestre G. Vaccine-induced, simian immunodeficiency virusspecific CD8+ T-cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. J. Immunol. 2009; 183:706–17. DOI: 10.4049/jimmunol.0803746..
DOI: 10.4049/jimmunol.0803746
Manrique M., Kozlowski P.A., Cobo-Molinos A., Wang S-W., Wilson R.L., Montefiori C., Mansfield K.G., Carville A., Aldovini A. Long-term control simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara. J. Immunol. 2011; 186:3581–93. DOI: 10.4049/jimmunol.1002594..
DOI: 10.4049/jimmunol.1002594
Manrique M., Kozlowski P.A., Cobo-Molinos A., Wang S-W., Wilson R.L., Martinez-Viedma M.P., Montefiori D.C., Carville A., Aldovini A. Resistance to infection, early and persistent suppression of Simian Immunodeficiency Virus SIVmac251 viremia and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques. J. Virol. 2014; 88(1):212–24. DOI: 10.1128/ jvi.02523-13..
DOI: 10.1128/ jvi.02523-13
Marthas M.L., Van Rompay K.K., Abbott Z., Earl P., Buonocore-Buzzelli L., Moss B., Rose N., Rose J., Kozlowski P.A., Abel K. Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. Vaccine. 2011; 29(17):3124–37. DOI: 10.1016/j.vaccine.2011.02.051..
DOI: 10.1016/j.vaccine.2011.02.051
Van Rompay K.K.A., Abel K., Earl P., Kozlowski P.A., Easlik J., Moore J., Buonocore-Buzzelli L., Schmidt K.A., Wilson R.L., Sivon I., Moss B., Rose N., Rose J., Marthas M.L. Immunogenicity of viral vector prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. Vaccine. 2010; 28(6):1481–92. DOI: 10.1016/j.vaccine.2009.11.061..
DOI: 10.1016/j.vaccine.2009.11.061
Berkley S.F., Koff W.C. Scientific and policy challenges to development of an AIDS vaccine. Lancet. 2007; 370:94–101. DOI: 10.1016/S0140-6736(07)61054-X..
DOI: 10.1016/S0140-6736(07)61054-X